Table 2.

Statistically significant (P < 0.05)a interactions between antioxidant SNPs and selenium supplementation for risk of high-grade prostate cancer (N = 1,109)

Genotype frequencyHR (95% CI) high-grade cancer
GeneGenotypeN (%) casesN (%) controlsPlacebo armSelenium armPb
CATrs10836233
GG145 (83.3%)750 (80.6%)1.01.02 (0.71–1.46)0.005
Any A29 (16.7%)180 (19.4%)0.38 (0.18–0.83)1.56 (0.90–2.71)
rs533425
GG58 (33.3%)351 (37.7%)1.02.58 (1.42–4.68)0.003
AG91 (52.3%)443 (47.6%)2.31 (1.29–4.13)2.28 (1.28–4.07)
AA25 (14.4%)136 (14.6%)2.35 (1.13–4.87)1.51 (0.67–3.37)
rs7944397
AA143 (82.7%)676 (72.8%)1.01.02 (0.71–1.46)0.02
Any G30 (17.3%)253 (27.2%)0.30 (0.14–0.62)0.93 (0.55–1.60)
PRDX6rs11580117
AA157 (89.7%)843 (90.3%)1.01.08 (0.75–1.54)0.05
any G18 (10.3%)91 (9.7%)0.72 (0.36–1.42)1.84 (1.09–3.13)
SOD2rs7855
AA157 (89.7%)843 (90.3%)1.01.46 (1.04–2.06)0.02
Any G18 (10.3%)91 (9.7%)2.14 (1.06–4.31)0.77 (0.31–1.88)
SOD3rs699473
TT73 (46.2%)379 (44.1%)1.02.18 (1.29–3.69)0.04
CT37 (23.4%)248 (28.8%)1.40 (0.75–2.63)1.11 (0.57–2.17)
CC48 (30.4%)233 (27.1%)1.68 (0.92–3.07)1.66 (0.88–3.11)
rs8192287
GG153 (87.4%)826 (88.5%)1.01.44 (1.02–2.03)0.04
any T22 (12.6%)107 (11.5%)1.69 (0.89–3.23)0.85 (0.39–1.87)
TXNRD2rs3804047
AA87 (50.9%)483 (52.8%)1.01.78 (1.12–2.84)0.03
AG72 (42.1%)355 (38.8%)1.48 (0.89–2.48)1.51 (0.91–2.50)
GG12 (7.0%)77 (8.4%)1.63 (0.67–3.94)0.91 (0.33–2.50)
rs8141691
GG65 (37.8%)398 (43.1%)1.01.64 (0.97–2.77)0.05
AG77 (44.8%)388 (42.0%)1.34 (0.78–2.31)1.76 (1.06–2.94)
AA30 (17.4%)138 (14.9%)2.18 (1.11–4.25)1.29 (0.65–2.56)
  • aFull results for all analyzed SNP × selenium assignment interactions are presented in Supplementary Table S2.

  • bP for test for interaction between SNP and selenium assignment for the outcome of risk of high-grade prostate cancer.